Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases, has announced that the first patient has been dosed in its phase 1/2 trial evaluating EO4010.
Launching in April last year, Cancer Research Horizons (CRH) describes itself as the “meeting point” between academia and industry, attempting to prevent drug discoveries from entering the ‘valley of death’ and stalling in their progress.
Immutep, a clinical-stage biotech company developing immunotherapies for cancer and autoimmune disease, has announced encouraging new clinical data in first-line non-small cell lung cancer from INSIGHT-003.
Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, will be presenting at the upcoming 2023 BIO International Convention in Boston.
LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting.
iOnctura, a clinical stage biotech company developing breakthrough therapies for cancer, has announced the peer-reviewed publication of translational research on the novel autotaxin (ATX) inhibitor IOA-289.
TILT Biotherapeutics, a biotech company developing cancer immunotherapies, has announced that the first patient has been dosed in a phase 1 trial of the company’s oncolytic adenovirus TILT-123.
Data from the company’s lead fibrosis asset called RXC700 has highlighted multiple opportunities for patients with pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC).
UCB and Ariceum have announced a strategic research collaboration to identify and develop systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.
Fusion Pharmaceuticals, a clinical-stage oncology company, has announced the opening of its new state-of-the-art radiopharmaceutical manufacturing facility at Ontario-based McMaster University.
The US-Chinese company Adcentrx Therapeutics has raised $38m in a Series A+ round to begin a phase 1 trial of its lead candidate antibody-drug conjugate (ADC) later this year.
The biotech startup Immune Bridge has bagged $12 million in a seed financing round to drive the development of natural killer (NK) cells that can be used in cell therapies for cancer.
Breath biopsy specialist, Owlstone Medical, has entered into a research agreement with biotech company, Bicycle Therapeutics plc, to access its bicyclic peptide technology.
The US biotech CytomX has lost a collaboration partner as AbbVie pulled out of a collaboration developing an antibody-drug conjugate (ADC) for the treatment of solid tumours.
BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications....
Oxford UK based Vaccitech reports positive topline interim data from a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
mRNA therapeutics have received increased amounts of attention and funding ever since mRNA vaccines proved effective in curbing the spread of the COVID-19 pandemic. Now, researchers are exploring mRNA therapeutics’ use in other disease spaces, reports...
The clinical stage biopharmaceutical company will use its RADR artificial intelligence (AI) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.
BioNTech and the UK government have signed a wide-reaching Memorandum of Understanding (MoU): with one of the goals to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030.
Synaffix, a Netherlands based company providing clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has signed off on two new licensing deals this week.
Pyxis Oncology has received clearance for two IND applications from the US Food and Drug Administration (FDA) to initiate two Phase 1 clinical studies.
Apollo Therapeutics and The Institute of Cancer Research in London have entered into a strategic collaboration to discover and develop new cancer medicines.
Emergence Therapeutics has become the tenth company to license ADC technology from Synaffix. The deal has a total potential value of up to US$360m, plus royalties on commercial sales.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) made several recommendations for approval of drugs and therapies at its June 2022 meeting.
Merck has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin, US.
A partnership with myNEO represents the first step in CureVac’s targeted expansion of its mRNA approach for the development of cancer vaccines, says the company.
The US agency has approved Enhertu for patients diagnosed with HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
Last week saw the US Food and Drug Administration (FDA) approve the Biologics License Application (BLA) from Amneal Pharmaceuticals Inc for bevacizumab-maly, a biosimilar referencing Avastin, the Roche/Genentech product.
Chinese companies, Biocytogen Pharmaceuticals and CtM Biotech Co Ltd, are collaborating on the development of antibody drugs against intracellular tumor-associated antigens.
The initiative is seeking proposals from final year MD, PhD students and postdoctoral researchers in relation to drug discovery and development across AstraZeneca’s core disease areas.
Celyad Oncology has decided to voluntarily pause dosing and enrollment of patients in the CYAD-101-002 trial in order to investigate reports of two patient deaths.
Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
Adaptimmune Therapeutics, which focuses on solid tumors, has announced a tie-up with Roche's Genentech to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.
